Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ADX10059

Small molecule · developed by Addex Pharma

Phase 2 Most advanced trial (none active)
ADXN Developer
1 Registered trials

What is ADX10059?

ADX10059 is a small-molecule antagonist of metabotropic glutamate receptor 5 (mGluR5). It was studied in gastroesophageal reflux disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Gastroenterology
Developer
Addex Pharma S.A. (ADXN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
66UCJ8Z8L1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00810485 Phase 2 Gastroesophageal Reflux Completed ADXN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gastroesophageal Reflux

More from Addex Pharma

Dipraglurant Phase 2/3

Follow ADXN, the company behind ADX10059

See ADXN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ADXN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.